Table 2. Results of node-splitting models for the test of difference between direct and indirect effect in the analysis of overall survival and toxic effects.
| Survival | Name | Direct effect | Idirect effect | Overall | P |
|---|---|---|---|---|---|
| 1-year survival | F, F + CRT | −0.48 (−1.66,0.60) | 0.47 (−0.68,1.58) | −0.06 (−0.93,0.83) | 0.19 |
| F, G | 0.13 (−0.69,0.90) | −0.84 (−1.78,0.07) | −0.25 (−1.09,0.45) | 0.08 | |
| F, OBS | −0.72 (−1.65,0.15) | −0.53 (−1.77,0.48) | −0.61 (−1.33,0.01) | 0.73 | |
| G, OBS | −0.03 (−0.73,0.65) | −1.01 (−2.06,0.01) | −0.36 (−1.04,0.38) | 0.10 | |
| 3-year survival | F, F + CRT | −0.33 (−1.22,0.69) | −0.07 (−1.14,0.91) | −0.25 (−0.90,0.45) | 0.74 |
| F, G | −0.04 (−0.86,0.76) | −0.20 (−1.12,0.75) | −0.07 (−0.59,0.41) | 0.8 | |
| F, OBS | −0.50 (−1.19,0.07) | −0.44 (−1.28,0.24) | −0.54 (−0.98,−0.04) | 0.81 | |
| G, OBS | −0.38 (−1.09,0.27) | −0.55 (−1.52,0.47) | −0.46 (−0.93,0.06) | 0.87 | |
| 5-year survival | F, F + CRT | −0.33 (−1.22,0.69) | −0.07 (−1.14,0.91) | −0.25 (−0.90,0.45) | 0.74 |
| F, G | −0.04 (−0.86,0.76) | −0.20 (−1.12,0.75) | −0.07 (−0.59,0.41) | 0.78 | |
| F, OBS | −0.50 (−1.19,0.07) | −0.44 (−1.28,−0.24) | −0.54 (−0.98,−0.04) | 0.81 | |
| G, OBS | −0.38 (−1.09,0.27) | −0.55 (−1.52,0.47) | −0.46 (−0.93,0.06) | 0.87 | |
| Toxic effect | F, F + CRT | 0.43 (−4.92,5.74) | −2.13 (−7.97,4.30) | −0.63 (−4.85,3.48) | 0.43 |
| F, G | −1.16 (−5.83,3.56) | 2.56 (−4.01,7.67) | −0.07, (−3.86,3.82) | 0.25 | |
| F, OBS | −3.00 (−9.28,3.10) | −3.81 (−8.64,1.25) | −3.60 (−7.43,0.33) | 0.82 | |
| G, OBS | −4.84 (−8.32,−0.97) | −1.16 (−7.22,5.03) | −3.65 (−7.04,−0.15) | 0.23 |
S, S-1; F, fluorouracil; G, gemcitabine, CRT, chemoradiation; C, Cisplatin; UFT, uracil/tegafur; NA, not available; *estimated from summary statistics.